Page 4 - Authorization Application News Today

Atara Biotherapeutics and French pharmaceutical company Pierre Fabre announced a commercialization partnership for Tab-cel, Atara’s off-the-shelf immunotherapy treatment for Epstein-Barr virus. The partnership will cover sales in Europe, the Middle East, Africa, and other emerging markets.

An authorization application submitted. it was developed last year, but it could have save lives. trey: thank you for coming on, thank you for giving to us straight. lets hope the holidays will be better than last, thank you so much for joining us. >> thank you, trey. trey: is our child welfare system failing the very children it purports to serve? what is in best interest of the child? who gets to decide? that is next on "sunday night in america." this is wealth. ♪ ♪ this is worth. that tak...

Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Phase

New Oxbryta, taking place online June 9-17, 2021. Results from an analysis of the Phase 2a HOPE-KIDS 1 Study (GBT440-007) in children with SCD ages 4 to 11 years treated with Oxbryta (voxelotor) tablets

Global Blood Therapeutics, Inc.: Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patient (voxelotor) Tablets Oxbryta (voxelotor) is an oral, once-daily therapy for patients with sickle cell disease (SCD). Oxbryta works by increasing hemoglobins affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, GBT belie...

Home / Top News / Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients SOUTH SAN FRANCISCO, Calif., ...

(1) In this collaboration Almirall will commercialize Wynzora Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply. MC2 Therapeutics and Almirall partner to make Wynzora Cream a leading topical product for Plaque Psoriasis in Europe In a large European based Phase 3 clinical trial (n=490), Wynzora Cream has demonstrated substantial efficacy with a PGA treatment success of 51% and beneficial treatment convenience 1 Cream h...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal ... Myovant Sciences, Inc.February 11, 2021 GMT ORGOVYX™ (relugolix) approved by the  U.S. Food and Drug Administration  (FDA) in December 2020 as the first and only oral GnRH receptor antagonist for adult patients with advanced prostate cancer; ORGOVYX launched in the U.S. in early January 2021 Announc...

Global Blood Therapeutics, Inc.: European Medicines Agency Accepts GBTs Marketing Authorization Application (MAA) for Oxbryta (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease (voxelotor) Tablets Oxbryta (voxelotor) is an oral, once-daily therapy for patients with sickle cell disease (SCD). Oxbryta works by increasing hemoglobins affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, GBT believes Oxbryta blocks polymerization and the resultant sickl...

Published: Jan 27, 2021 SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that the European Medicines Agency (EMA) has completed the validation of GBT’s Marketing Authorization Application (MAA) for Oxbryta ® (voxelotor) tablets and started its standard review process. GBT is seeking full marketing approval from the EMA for Oxbryta to treat hemolytic anemia in patients with sickle cell disease (SCD) who are...